银屑病患者抑郁症状、抑郁症及生物制剂治疗的影响:PSOLAR登记研究
在PSOLAR登记中,评估中重度银屑病患者抑郁症状发生率及治疗影响。生物制剂、光疗和传统系统治疗的抑郁症状发生率分别为每100患者年3.01、5.85和5.70。与传统治疗相比,生物制剂降低抑郁症状风险(HR 0.76,95%CI 0.59-0.98),光疗无此效应。
要点
- 生物制剂组抑郁症状发生率低于传统系统治疗和光疗组。
- 生物制剂较传统治疗降低抑郁症状风险(HR 0.76,95%CI 0.59-0.98)。
- 光疗未显示降低抑郁症状风险(HR 1.05,95%CI 0.71-1.54)。
核心结论
- 与传统治疗相比,生物制剂可能降低银屑病患者抑郁症状的发生率。
研究设计与样本
- 基于银屑病纵向评估与登记(PSOLAR)的研究人群,比较生物制剂、传统系统治疗或光疗队列。
- 每约6个月评估一次,采用多变量模型确定治疗对风险的影响。
主要发现
- 抑郁症状发生率:生物制剂每100患者年3.01(95%CI 2.73-3.32),光疗5.85(95%CI 4.29-7.97),传统治疗5.70(95%CI 4.58-7.10)。
- 与传统治疗相比,生物制剂降低抑郁症状风险(HR 0.76,95%CI 0.59-0.98),光疗无显著影响(HR 1.05,95%CI 0.71-1.54)。
- 抑郁不良事件发生率:生物制剂每100患者年0.21(95%CI 0.15-0.31),光疗0.55(95%CI 0.21-1.47),传统治疗0.14(95%CI 0.03-0.55),事件数仅37例无法建模。
关键数值与推荐
- 抑郁症状定义为医院焦虑抑郁量表-抑郁评分≥8。
临床怎么用
- 对中重度银屑病患者,选择生物制剂可能有助于降低抑郁症状风险。
局限性
- 登记中对抑郁和混杂因素的捕获不完整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with psoriasis are at an increased risk for depression. However, the impact of treatment on this risk is unclear. OBJECTIVE: Evaluate the incidence and impact of treatment on depression among patients with moderate-to-severe psoriasis. METHODS: We defined a study population within the Psoriasis Longitudinal Assessment and Registry and measured the incidence of depressive symptoms (Hospital Anxiety and Depression Scale-Depression score ≥8) and adverse events (AEs) of depression within cohorts receiving biologics, conventional systemic therapies, or phototherapy. Patients were evaluated at approximately 6-month intervals. Multivariate modeling determined the impact of treatment on risk. RESULTS: The incidence rates of depressive symptoms were 3.01 per 100 patient-years (PYs) (95% confidence interval [CI], 2.73-3.32), 5.85 per 100 PYs (95% CI, 4.29-7.97), and 5.70 per 100 PYs (95% CI, 4.58-7.10) for biologics, phototherapy, and conventional therapy, respectively. Compared with conventional therapy, biologics reduced the risk for depressive symptoms (hazard ratio, 0.76; 95% CI, 0.59-0.98), whereas phototherapy did not (hazard ratio, 1.05; 95% CI, 0.71-1.54). The incidence rates for AEs of depression were 0.21 per 100 PYs (95% CI, 0.15-0.31) for biologics, 0.55 per 100 PYs (95% CI, 0.21-1.47) for phototherapy, and 0.14 per 100 PYs (95% CI, 0.03-0.55) for conventional therapy; the fact that there were too few events (37 AEs) precluded modeling. LIMITATIONS: Incomplete capture of depression and confounders in the patients on registry. CONCLUSION: Compared with conventional therapy, biologics appear to be associated with a lower incidence of depressive symptoms among patients with psoriasis.
引用
- Strober B, Gooderham M, de Jong EMGJ, et al. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Am Acad Dermatol. 2017. PMID: 29102053. doi:10.1016/j.jaad.2017.08.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。